Business Strategy
The NTT drug delivery platform provides the basis for NTT to develop independently proprietary products that are available for late stage out-licensing or co-development, as well as providing a wide variety of development partnership opportunities for companies seeking proved transdermal technologies for in-house development.
In addition, NTT develops, manufactures, and in conjunction with its marketing partners, sells products incorporating the Ethosome and the Web-like technology for pharmaceutical and cosmetic applications.
NTT proprietary technology offers opportunities for revenues over the short, medium, and long terms:
Sources of revenue in the short to medium term: § Potential upfront and milestone payments on out-licensing transactions with pharmaceutical and biotechnology companies; and
§ Revenues from private label cosmetic formulation sales.
Additional sources of revenue in the medium to longer term:
§ Potential royalty streams and further milestone payments from out-licensing deals; and
§ Additional out-licensing of New Drug Applications developed in-house.
The Ethosome technology is protected under international patents. Newer specific applications and second generation delivery patents (Web-like technology )have also been developed by Novel Therapeutic Technologies as new business opportunities in the field of infection. Other topical applications are developed to leverage the existing Ethosome Patents.